[1]
Hoffman E.P., Brown R.H., JR., Kunkel L.M.: Dystrophin: the protein
product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-
928.
[1]
Hoffman E.P., Brown R.H., JR., Kunkel L.M.: Dystrophin: the protein
product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-
928.
[2]
Emery A.E.: Population frequencies of inherited neuromuscular
diseases--a world survey. Neuromuscul Disord 1991; 1: 19-29.
[2]
Emery A.E.: Population frequencies of inherited neuromuscular
diseases--a world survey. Neuromuscul Disord 1991; 1: 19-29.
[3]
Bushby K., Finkel R., Birnkrant D.J., et al.: Diagnosis and management of
Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological
and psychosocial management. Lancet Neurol 2010; 9: 77-93.
[3]
Bushby K., Finkel R., Birnkrant D.J., et al.: Diagnosis and management of
Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological
and psychosocial management. Lancet Neurol 2010; 9: 77-93.
[4]
Bushby K., Finkel R., Birnkrant D.J., et al.: Diagnosis and management
of Duchenne muscular dystrophy, part 2: implementation of
multidisciplinary care. Lancet Neurol 2010; 9: 177-189.
[4]
Bushby K., Finkel R., Birnkrant D.J., et al.: Diagnosis and management
of Duchenne muscular dystrophy, part 2: implementation of
multidisciplinary care. Lancet Neurol 2010; 9: 177-189.
[5]
Zimowski J.G., Holding M., Fidzianska E., et al.: [Detection of rare
mutations in the dystrophin gene]. Med Wieku Rozwoj 2009; 13: 140-
145.
[5]
Zimowski J.G., Holding M., Fidzianska E., et al.: [Detection of rare
mutations in the dystrophin gene]. Med Wieku Rozwoj 2009; 13: 140-
145.
[6]
Janssen B., Hartmann C., Scholz V., et al.: MLPA analysis for the
detection of deletions, duplications and complex rearrangements in the
dystrophin gene: potential and pitfalls. Neurogenetics 2005; 6: 29-35.
[6]
Janssen B., Hartmann C., Scholz V., et al.: MLPA analysis for the
detection of deletions, duplications and complex rearrangements in the
dystrophin gene: potential and pitfalls. Neurogenetics 2005; 6: 29-35.
[7]
Mcmillan H.J., Campbell C., Mah J.K.: Duchenne muscular dystrophy:
Canadian paediatric neuromuscular physicians survey. Can J Neurol Sci
2010; 37: 195-205.
[7]
Mcmillan H.J., Campbell C., Mah J.K.: Duchenne muscular dystrophy:
Canadian paediatric neuromuscular physicians survey. Can J Neurol Sci
2010; 37: 195-205.
[8]
Manzur A.Y., Kuntzer T., Pike M., et al.: Glucocorticoid corticosteroids
for Duchenne muscular dystrophy. Cochrane Database Syst Rev
2008;CD003725.
[8]
Manzur A.Y., Kuntzer T., Pike M., et al.: Glucocorticoid corticosteroids
for Duchenne muscular dystrophy. Cochrane Database Syst Rev
2008;CD003725.
[9]
Lit L., Sharp F.R., Apperson M., et al.: Corticosteroid effects on blood
gene expression in Duchenne muscular dystrophy. Pharmacogenomics
J 2009; 9: 411-418.
[9]
Lit L., Sharp F.R., Apperson M., et al.: Corticosteroid effects on blood
gene expression in Duchenne muscular dystrophy. Pharmacogenomics
J 2009; 9: 411-418.
[10]
Hussein M.R., Abu-Dief E.E., Kamel N.F., et al.: Steroid therapy is
associated with decreased numbers of dendritic cells and fibroblasts,
and increased numbers of satellite cells, in the dystrophic skeletal
muscle. J Clin Pathol 2010; 63: 805-813.
[10]
Hussein M.R., Abu-Dief E.E., Kamel N.F., et al.: Steroid therapy is
associated with decreased numbers of dendritic cells and fibroblasts,
and increased numbers of satellite cells, in the dystrophic skeletal
muscle. J Clin Pathol 2010; 63: 805-813.
[11]
Drachman D.B., Toyka KV., Myer E.: Prednisone in Duchenne muscular
dystrophy. Lancet 1974; 2: 1409-1412.
[11]
Drachman D.B., Toyka KV., Myer E.: Prednisone in Duchenne muscular
dystrophy. Lancet 1974; 2: 1409-1412.
[12]
Biggar W.D., Harris V.A., Eliasoph L., et al.: Long-term benefits of
deflazacort treatment for boys with Duchenne muscular dystrophy in
their second decade. Neuromuscul Disord 2006; 16: 249-255.
[12]
Biggar W.D., Harris V.A., Eliasoph L., et al.: Long-term benefits of
deflazacort treatment for boys with Duchenne muscular dystrophy in
their second decade. Neuromuscul Disord 2006; 16: 249-255.
[13]
Moxley R.T., III, Ashwal S., Pandya S., et al.: Practice parameter:
corticosteroid treatment of Duchenne dystrophy: report of the Quality
Standards Subcommittee of the American Academy of Neurology and
the Practice Committee of the Child Neurology Society. Neurology 2005;
64: 13-20.
[13]
Moxley R.T., III, Ashwal S., Pandya S., et al.: Practice parameter:
corticosteroid treatment of Duchenne dystrophy: report of the Quality
Standards Subcommittee of the American Academy of Neurology and
the Practice Committee of the Child Neurology Society. Neurology 2005;
64: 13-20.
[14]
Moxley R.T., III, Pandya S., Ciafaloni E., et al.: Change in natural history of
Duchenne muscular dystrophy with long-term corticosteroid treatment:
implications for management. J Child Neurol 2010; 25: 1116-1129.
[14]
Moxley R.T., III, Pandya S., Ciafaloni E., et al.: Change in natural history of
Duchenne muscular dystrophy with long-term corticosteroid treatment:
implications for management. J Child Neurol 2010; 25: 1116-1129.
[15]
Escolar D.M., Hache L.P., Clemens P.R., et al.: Randomized, blinded
trial of weekend vs daily prednisone in Duchenne muscular dystrophy.
Neurology 2011; 77: 444-452.
[15]
Escolar D.M., Hache L.P., Clemens P.R., et al.: Randomized, blinded
trial of weekend vs daily prednisone in Duchenne muscular dystrophy.
Neurology 2011; 77: 444-452.
[16]
Straathof C.S., Overweg-Plandsoen W.C., Van Den Burg G.J., et al.:
Prednisone 10 days on/10 days off in patients with Duchenne muscular
dystrophy. J Neurol 2009; 256: 768-773.
[16]
Straathof C.S., Overweg-Plandsoen W.C., Van Den Burg G.J., et al.:
Prednisone 10 days on/10 days off in patients with Duchenne muscular
dystrophy. J Neurol 2009; 256: 768-773.
[17]
Beenakker E.A., Fock J.M., Van Tol M.J., et al.: Intermittent prednisone
therapy in Duchenne muscular dystrophy: a randomized controlled trial.
Arch Neurol 2005; 62: 128-132.
[17]
Beenakker E.A., Fock J.M., Van Tol M.J., et al.: Intermittent prednisone
therapy in Duchenne muscular dystrophy: a randomized controlled trial.
Arch Neurol 2005; 62: 128-132.
[18]
Biggar W.D., Politano L., Harris V.A., et al.: Deflazacort in Duchenne
muscular dystrophy: a comparison of two different protocols.
Neuromuscul Disord 2004; 14: 476-482.
[18]
Biggar W.D., Politano L., Harris V.A., et al.: Deflazacort in Duchenne
muscular dystrophy: a comparison of two different protocols.
Neuromuscul Disord 2004; 14: 476-482.
[19]
Biggar W.D., Gingras M., Fehlings D.L., et al.: Deflazacort treatment of
Duchenne muscular dystrophy. J Pediatr 2001; 138: 45-50.
[19]
Biggar W.D., Gingras M., Fehlings D.L., et al.: Deflazacort treatment of
Duchenne muscular dystrophy. J Pediatr 2001; 138: 45-50.
[20]
Markham L.W., Kinnett K., Wong B.L., et al.: Corticosteroid treatment
retards development of ventricular dysfunction in Duchenne muscular
dystrophy. Neuromuscul Disord 2008; 18: 365-370.
[20]
Markham L.W., Kinnett K., Wong B.L., et al.: Corticosteroid treatment
retards development of ventricular dysfunction in Duchenne muscular
dystrophy. Neuromuscul Disord 2008; 18: 365-370.
Scholar Google
PubMed